I bought HZNP at 2.04 10 days ago (now $2.48), they have two FDA approved drugs and languished after approval, to $1.97. Now it's headed up, should be an easy double from here, likely more if you hold longer this year.
Sentiment: Strong Buy
TSRX has wrapped enrollment on 2nd Phase 3, has QIDP, and is the safest bet for a double among the biotechs I follow. Extremely undervalued given likelihood of approval for Tedzolid, more potent, safer alternative to Linezolid. They have both IV and oral formulation data and current trail comparing 6day daily vs 10 day BID (Linezolid). Stock beat up over dilution last year. Be warned, even with approval they are not the only kids in the sand box but I like my chances.
MACK looks very promising but years away. Network Biology platform invokes proprietary computational models tapping the Cambridge area think tank. They are going after everything which is expensive in Oncology but Sanofi is a partner on MM-111 and MM121 so they are footing most of the bill. ML already has coverage through R. McGinn. Bulk of hopes ly on the success of targeting Erb3. They first caught my eye on Fierce Biotech because they were buying back Ex Us Rights before they went public. Very impressive pipeline. MM-398, farthest advanced but not why I'm involved. Don't jump in with two feet, no need given catalyst no time soon.